Alkem Laboratories Ltd.
NSE: ALKEM · Pharmaceuticals
Snapshot
Unlock Alkem Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alkem Laboratories is a pharmaceutical company that develops, manufactures, and markets a diverse range of branded generics, active pharmaceutical ingredients, and nutraceuticals. Its portfolio spans various therapeutic areas including anti-infectives, gastro-intestinal, pain management, and chronic care segments.
Business Model
The company generates revenue through the sale of pharmaceutical products across domestic and international markets, leveraging a broad portfolio of acute and chronic therapeutic offerings. It operates through a vertically integrated model that encompasses research, development, and manufacturing of both drugs and consumer health products.
Growth Outlook
Growth is driven by the expansion of the company's chronic therapy portfolio and the continued strengthening of its branded generics business in India. International market penetration and the development of biosimilars serve as additional levers for long-term value creation.
Key Risks
- Regulatory Compliance. The company faces significant risks from stringent inspections by global health authorities like the USFDA, which can impact manufacturing operations and export capabilities.
- Pricing Pressure. Government-mandated price controls on essential medicines in the Indian market can compress profit margins and limit revenue growth.
- Currency Volatility. As an exporter with international operations, the company is exposed to fluctuations in foreign exchange rates that may impact financial performance.
- Competitive Landscape. The pharmaceutical sector is highly fragmented and competitive, necessitating continuous investment in research and development to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Alkem Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹15,081 Cr
TTM · consolidated
NET PROFIT
₹2,204 Cr
TTM · consolidated
EPS
₹180.44
TTM · consolidated
RETURN ON EQUITY
17.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
20.5%
TTM · consolidated
P/E
28.8x
Q1 FY27 · consolidated
EV/EBITDA
17.5x
Q1 FY27 · consolidated
EBITDA MARGIN
24.1%
TTM · consolidated
NET PROFIT MARGIN
13.9%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Alkem Laboratories Ltd.ALKEM | ₹62,054 Cr | 28.76 | 17.47 | 13.4% | 24.1% | 17.1% | 20.5% | -2.1% |
Glenmark Pharmaceuticals Ltd.GLENMARK | ₹68,778 Cr | 38.25 | 12.76 | 32.9% | 29.9% | 18.6% | 23.2% | +22.4% |
Biocon Ltd.BIOCON | ₹64,415 Cr | 116.88 | 19.93 | 9.8% | 22.2% | 1.5% | 3.0% | +11.4% |
Abbott India Ltd.ABBOTINDIA | ₹55,386 Cr | 35.69 | 25.20 | 8.1% | 31.5% | 35.5% | 45.4% | -19.0% |
Glaxosmithkline Pharmaceuticals Ltd.GLAXO | ₹50,112 Cr | 47.70 | 32.70 | 5.8% | 37.9% | 50.6% | 61.2% | +3.7% |
Ipca Laboratories Ltd.IPCALAB | ₹49,860 Cr | 38.07 | 20.90 | 10.6% | 23.7% | 18.3% | 19.4% | +46.8% |
As of Q1 FY27
Financials
Alkem Laboratories Ltd.
NSE: ALKEM · Pharmaceuticals
Snapshot
Unlock Alkem Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alkem Laboratories is a pharmaceutical company that develops, manufactures, and markets a diverse range of branded generics, active pharmaceutical ingredients, and nutraceuticals. Its portfolio spans various therapeutic areas including anti-infectives, gastro-intestinal, pain management, and chronic care segments.
Business Model
The company generates revenue through the sale of pharmaceutical products across domestic and international markets, leveraging a broad portfolio of acute and chronic therapeutic offerings. It operates through a vertically integrated model that encompasses research, development, and manufacturing of both drugs and consumer health products.
Growth Outlook
Growth is driven by the expansion of the company's chronic therapy portfolio and the continued strengthening of its branded generics business in India. International market penetration and the development of biosimilars serve as additional levers for long-term value creation.
Key Risks
- Regulatory Compliance. The company faces significant risks from stringent inspections by global health authorities like the USFDA, which can impact manufacturing operations and export capabilities.
- Pricing Pressure. Government-mandated price controls on essential medicines in the Indian market can compress profit margins and limit revenue growth.
- Currency Volatility. As an exporter with international operations, the company is exposed to fluctuations in foreign exchange rates that may impact financial performance.
- Competitive Landscape. The pharmaceutical sector is highly fragmented and competitive, necessitating continuous investment in research and development to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Alkem Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹15,081 Cr
TTM · consolidated
NET PROFIT
₹2,204 Cr
TTM · consolidated
EPS
₹180.44
TTM · consolidated
RETURN ON EQUITY
17.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
20.5%
TTM · consolidated
P/E
28.8x
Q1 FY27 · consolidated
EV/EBITDA
17.5x
Q1 FY27 · consolidated
EBITDA MARGIN
24.1%
TTM · consolidated
NET PROFIT MARGIN
13.9%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27